GLP-1 drugs and IVF: what the evidence actually supports

What's this video probably claiming?

Based on the hashtag cluster here, @doc.ivf is almost certainly walking through the case for using GLP-1 receptor agonists, likely semaglutide or tirzepatide, as a pre-IVF weight loss tool, particularly for patients with PCOS. The framing probably goes something like: losing weight before a retrieval cycle improves outcomes, GLP-1s are the best tool we have for that right now, therefore GLP-1s before IVF makes sense. That logic chain is not wrong on its face. But the creator is likely glossing over some genuinely important gaps, including the fact that there is essentially zero long-term safety data on these drugs in early pregnancy, and that most fertility clinics require patients to stop GLP-1 medications well before egg retrieval or embryo transfer. The combination of hashtags like #glpivf and #ttcjourney suggests this is pitched at patients actively trying to conceive, which raises the stakes considerably for accuracy.

What does the science actually show?

The fertility-adjacent evidence for GLP-1s is real but narrow. A 2023 analysis published in Human Reproduction (Sermondade et al.) found that obesity is independently associated with lower clinical pregnancy rates and higher miscarriage risk in IVF cycles, so weight reduction before treatment has a legitimate rationale. Semaglutide produces roughly 15% body weight reduction at 68 weeks in non-diabetic patients (Wilding et al., 2021, NEJM), and tirzepatide edges that to around 20-22% (Jastreboff et al., 2022, NEJM). For a patient with PCOS and a BMI over 35, those numbers can be clinically meaningful before an IVF cycle. What the evidence does not show is that GLP-1s directly improve egg quality, embryo development, or live birth rates. Those studies do not exist yet in any adequately powered form. The mechanism is weight-mediated, not direct. That distinction matters enormously when you're counseling someone spending $15,000-$25,000 on a cycle.

Where does the social media noise diverge from clinical reality?

The #glpivf framing implies a protocol that most reproductive endocrinologists would not recognize as standard of care. The American Society for Reproductive Medicine has not issued formal guidance specifically on GLP-1s before IVF as of early 2025. Most REIs are telling patients to discontinue semaglutide or tirzepatide at least two months before a retrieval cycle because of delayed gastric emptying, aspiration risk under anesthesia, and theoretical concerns about fetal exposure during the luteal phase. GLP-1 drugs carry a pregnancy category warning, and animal studies have shown fetal harm at supratherapeutic doses, though that data doesn't cleanly translate to humans. TikTok creators in the fertility space tend to collapse the pre-IVF weight loss phase and the active IVF cycle into one continuous narrative, which obscures the fact that you generally cannot be on these drugs when you're actually cycling. That's a meaningful clinical detail that gets lost in the #glpivf hype.

What should you actually know?

If you have PCOS and are preparing for IVF, weight loss before your cycle is a reasonable goal with real evidence behind it. GLP-1 receptor agonists are among the more effective tools available for that, particularly for patients who have struggled with weight loss through diet and exercise alone. But a few things need to be said plainly. First, you need to stop these medications before your retrieval cycle, and your clinic will likely require a washout period of at least 8-12 weeks. Second, no study has demonstrated that GLP-1s improve live birth rates in IVF patients directly. The benefit is indirect and works through weight reduction. Third, compounded semaglutide or tirzepatide products are not the same as FDA-approved Wegovy or Zepbound, and quality control across compounders varies substantially. Talk to a reproductive endocrinologist before starting any weight loss medication with a TTC timeline in mind. TikTok, including well-intentioned clinician creators, is not a substitute for that conversation.